Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

Table 3 NASH therapies in clinical trials

	Description	Target	Phase	Duration
Obeticholic acid	Semisynthetic bile acid	FXR agonist	III^a	72 weeks
Elafibranor	Small-molecule	Dual PPAR α/δ agonist	III	72 weeks
Resmetirom	Small-molecule	THR β agonist	III	52 weeks
Aramchol	Synthetic FABAC	SCD-1 modulator	III	52 weeks
Cenicriviroc	Small-molecule	Dual CCR2/CCR5 antagonist	III	48 weeks

Abbreviations: NASH Nonalcoholic steatohepatitis, FXR Farnesoid x receptor, PPAR Peroxisome proliferator-activated receptor, THR Thyroid hormone receptor, FABAC Fatty-acid/bile-acid conjugate, SCD Stearoyl-CoA desaturase, CCR C-c chemokine receptor
^aTopline results demonstrated significant improvement in fibrosis by 1 stage in patients on OCA 25 mg daily compared to those in the placebo arm [103]

ISSN: 2055-8260